ImmunityBio, Inc. SEC filings IBRX
ImmunityBio, Inc. has 554 filings in SEC EDGAR's recent list, going back to Apr 29, 2005. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 2, 2024 | — |
| CORRESP | Letter to the SEC | Apr 30, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2024 | — |
| CORRESP | Letter to the SEC | Mar 28, 2024 | — |
| D | Filing | Sep 22, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 8, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2023 | — |
| CORRESP | Letter to the SEC | Jan 5, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2022 | — |
| D | Filing | Jul 22, 2022 | — |
| EFFECT | Filing | May 18, 2022 | — |
| POS EX | Filing | May 18, 2022 | — |
| AW | Filing | May 18, 2022 | — |
| POSASR | Filing | Mar 1, 2022 | — |
| EFFECT | Filing | May 26, 2021 | — |
| 425 | Filing | Mar 8, 2021 | — |
| 425 | Filing | Mar 2, 2021 | — |
| 425 | Filing | Feb 25, 2021 | — |
| 425 | Filing | Feb 25, 2021 | — |
| 425 | Filing | Feb 24, 2021 | — |
| EFFECT | Filing | Feb 1, 2021 | — |
| 425 | Filing | Jan 13, 2021 | — |
| 425 | Filing | Dec 22, 2020 | — |
| 425 | Filing | Dec 22, 2020 | — |
| 425 | Filing | Dec 21, 2020 | — |
| 425 | Filing | Dec 21, 2020 | — |
| 425 | Filing | Dec 21, 2020 | — |
| EFFECT | Filing | Sep 3, 2019 | — |
| CORRESP | Letter to the SEC | Aug 29, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2019 | — |
| EFFECT | Filing | Aug 26, 2016 | — |
| CORRESP | Letter to the SEC | Aug 23, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2016 | — |
| D | Filing | Aug 5, 2015 | — |
| CT ORDER | Filing | Jul 28, 2015 | — |
| EFFECT | Filing | Jul 27, 2015 | — |
| CERTNAS | Auto-generated paper document | Jul 24, 2015 | — |
| CORRESP | Letter to the SEC | Jul 24, 2015 | — |
| CORRESP | Letter to the SEC | Jul 24, 2015 | — |
| 8-A12B | Filing | Jul 20, 2015 | — |
| D/A | Filing | Jul 17, 2015 | — |
| CORRESP | Letter to the SEC | Jul 15, 2015 | — |
| CORRESP | Letter to the SEC | Jul 13, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2015 | — |
| CORRESP | Letter to the SEC | Jul 6, 2015 | — |
| CORRESP | Letter to the SEC | Jul 2, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2015 | — |
| D | Filing | Jun 24, 2015 | — |
| CORRESP | Letter to the SEC | Jun 19, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2015 | — |
| DRS | Filing | May 14, 2015 | — |
| D | Filing | Jan 5, 2015 | — |
| D | Filing | Dec 29, 2014 | — |
| D | Filing | Apr 17, 2014 | — |
| D | Filing | Oct 9, 2009 | — |
| REGDEX | Auto-generated paper document | Apr 29, 2005 | — |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1326110
- Former names
- NantKwest, Inc. (until Mar 8, 2021); Conkwest, Inc. (until Jul 13, 2015); ZelleRx Corp (until Oct 9, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.